JURÁŇ, Vilém, Barbora KOHLOVÁ, Martin PISKÁČEK, Vít ZMÁTLO, Leonard JAKUBÁČ, Veronika MOTÚZOVÁ, Marie TOMANDLOVÁ, Marek SOVA, Tomáš KAZDA, Václav VYBÍHAL, Pavel FADRUS a Andrea KNIGHT. Infiltration of Gamma-delta T cells into Glioblastoma Tumor. Online. In WFNOS 2022 - the World Federation of Neuro-Oncology Societies (WFNOS), Seoul, South Korea. 2021, [citováno 2024-04-23]
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Infiltration of Gamma-delta T cells into Glioblastoma Tumor
Autoři JURÁŇ, Vilém, Barbora KOHLOVÁ, Martin PISKÁČEK, Vít ZMÁTLO, Leonard JAKUBÁČ, Veronika MOTÚZOVÁ, Marie TOMANDLOVÁ, Marek SOVA, Tomáš KAZDA, Václav VYBÍHAL, Pavel FADRUS a Andrea KNIGHT
Vydání WFNOS 2022 - the World Federation of Neuro-Oncology Societies (WFNOS), Seoul, South Korea, 2021.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Utajení není předmětem státního či obchodního tajemství
Organizační jednotka Lékařská fakulta
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 26. 1. 2022 12:40.
Anotace
Gamma-delta (γδ) T cells are innate immunity effector lymphocytes with known prominent anti-tumor reactivity against aggressive glioblastoma (GBM). However, therapeutic approaches have had limited success due to the protective blood-brain-barrier and the immunosuppressive GBM tumor microenvironment. In this study, we determined Vδ1 a Vδ2 γδ T cell populations in peripheral blood and paired tumor tissue samples in patients (n=40) following the resection and throughtout the therapy follow-up. Tumor samples were processed using enzymatic kits and gentleMACSTM Dissociator (Miltenyi Biotec Inc.) and tumor-infiltrating γδ T lymphocytes (TILs) were analyzed by flow cytometry. We found infiltration of both intratumoral CD3+ γδ T cell subsets in 68% tumor samples. We detected Vδ1 γδ T cells in the range 0-0.8% (median 0.26%). Majority of GBM patients presented the Vδ2 subset among TILs in the range 0-13.8% (median 1.5%). Functional studies showed prominent cytotoxicity of magnetically sorted Vδ1 a Vδ2 γδ T cells against GBM cell lines and more importantly against primary tumors. Detailed phenotypic profiling and single-cell sequencing of Vδ2 γδ T cells is currently underway. Next, we identified the EphA2 receptor as one of the targets for tumor-reactive Vδ1 γδ T cells. Specifically, we found that blocking of EphA2 expression resulted in significant inhibition of GBM killing mediated by Vδ1 γδ T cells. Furthermore, multiplex analysis of soluble proteins in patients‘ plasma samples determined by Luminex® 200™ has identified significantly elevated levels of stress ligand MICA and check-point inhibitor ligands PD-L1 (B7-H1, CD274) and B7-H3 (CD276). The patient’s clinical course and therapeutic protocols will be discussed.
Návaznosti
NV19-05-00410, projekt VaVNázev: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme
Investor: Ministerstvo zdravotnictví ČR, Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme
VytisknoutZobrazeno: 23. 4. 2024 17:20